Core Viewpoint - Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Baoyi Pharmaceutical-B (02659) being included in the Hang Seng Composite Index, effective March 9, 2026 [1] Company Summary - Baoyi Pharmaceutical has developed China's first marketed recombinant hyaluronidase KJ017 for large-volume subcutaneous administration, and the world's first IgG degrading enzyme KJ103, which has "best-in-class" potential in terms of low pre-stored antibodies and administration frequency for antibody-mediated autoimmune diseases [1] - The company also has a long-acting follicle-stimulating hormone drug SJ02, which has been validated through collaboration for assisted reproduction [1] - These three core products are in various stages of commercialization, new drug application registration, or later clinical stages in China, indicating a transition from pure research and development to commercialization for Baoyi Pharmaceutical [1] Industry Summary - The adjustment of Hong Kong Stock Connect eligible stocks is often seen as a market barometer [1] - If Baoyi Pharmaceutical successfully enters the Stock Connect, it is expected to significantly enhance stock liquidity and valuation premium, providing mainland investors with new opportunities to allocate quality biopharmaceutical assets [1]
宝济药业-B(02659)获纳入恒生综合指数 有望入选港股通开启价值重估